AnimAb is registered with the CBE as active in: Vervaardiging van geneesmiddelen. Private Limited, started on 27 May 2020, 1 establishment.

What is the address of AnimAb?

The registered office of AnimAb is located at Technologiepark-Zwijnaarde 94, 9052 Gent.

Is AnimAb still active?

Yes. According to the CBE (29 October 2026) AnimAb is active, legal situation “Normale toestand”, started on 27 May 2020.

Is AnimAb registered on Peppol?

Yes, AnimAb is registered on the Peppol network with ID 0208:0747674614.

What is the enterprise number of AnimAb?

The enterprise number of AnimAb is BE0747674614.

When was AnimAb founded?

AnimAb was founded on 27 May 2020.

Who are the directors of AnimAb?

According to the 2025 annual accounts, the directors of AnimAb are: Virtus Bonarum Cellarum BV, Participatiemaatschappij Vlaanderen NV, ALBATROS BV, SLL Consulting LLC, Agri Investment Fund BV, QBIC Venture Partners III.

Is AnimAb a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 May 2020; 5 annual accounts filed, latest fiscal year 2025; 6 directors known from the annual account.

How much profit did AnimAb make in 2025?

AnimAb recorded a loss after taxes of € 5,302,654 in financial year 2025.

What is the revenue of AnimAb?

As a small company, AnimAb is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 28,596.

How much does an employee at AnimAb earn?

The average wage cost per full-time employee at AnimAb was € 101,400 in 2025: staff costs of € 567,777 for 5.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does AnimAb have?

According to the 2025 annual accounts, AnimAb has 5.6 full-time equivalents (FTE).

AnimAb (Private Limited) - Gent - BE0747674614

Dossier AnimAb, printed on 29 October 2026 from databakkes.be/en/0747674614/animab. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

AnimAb from Gent, company number BE0747674614, closed financial year 2025 with a result of € -5.3 million after tax. For that financial year AnimAb recorded a gross margin of € 28,596 and equity of € 2.8 million. Compared with financial year 2024, the result moved from € -3.8 million to € -5.3 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.

What it is worth Healthy

€ 2.8 million

▼ 32% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -5.3 million

▼ 39 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.8 million

▼ 47% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -15.3 million.

People and assets in 2025

Full-time equivalents

5.6

▲ 0.9 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 567,777

▲ 23% vs 2024

€ 101,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 3,354

▼ 44% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 627,722

▲ 35% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 81,156

▲ 27% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 503,327 Gross margin 2022: € 503,327 First fiscal year in the series	€ 384,157 Gross margin 2023: € 384,157 ▼ 24% vs 2022 (€ 503,327) Unfavourable step	€ 633,786 Gross margin 2024: € 633,786 ▲ 65% vs 2023 (€ 384,157) Favourable step	€ 28,596 Gross margin 2025: € 28,596 ▼ 95% vs 2024 (€ 633,786) Unfavourable step	▼ 95%
Profit after taxes	€ -1,628,945 Profit after taxes 2022: € -1,628,945 First fiscal year in the series	€ -2,624,565 Profit after taxes 2023: € -2,624,565 ▼ € 995,620 vs 2022 (€ -1,628,945) Unfavourable step	€ -3,814,972 Profit after taxes 2024: € -3,814,972 ▼ € 1.2 million vs 2023 (€ -2,624,565) Unfavourable step	€ -5,302,654 Profit after taxes 2025: € -5,302,654 ▼ € 1.5 million vs 2024 (€ -3,814,972) Unfavourable step	▼ € 1.5 million
Equity	€ 6,302,067 Equity 2022: € 6,302,067 First fiscal year in the series	€ 3,677,502 Equity 2023: € 3,677,502 ▼ 42% vs 2022 (€ 6,302,067) Unfavourable step	€ 4,062,530 Equity 2024: € 4,062,530 ▲ 10% vs 2023 (€ 3,677,502) Favourable step	€ 2,759,876 Equity 2025: € 2,759,876 ▼ 32% vs 2024 (€ 4,062,530) Unfavourable step	▼ 32%
Total debts	€ 368,111 Total debts 2022: € 368,111 First fiscal year in the series	€ 444,015 Total debts 2023: € 444,015 ▲ 21% vs 2022 (€ 368,111) Unfavourable step	€ 529,256 Total debts 2024: € 529,256 ▲ 19% vs 2023 (€ 444,015) Unfavourable step	€ 708,878 Total debts 2025: € 708,878 ▲ 34% vs 2024 (€ 529,256) Unfavourable step	▲ 34%
Cash	€ 5,428,983 Cash 2022: € 5,428,983 First fiscal year in the series	€ 3,227,578 Cash 2023: € 3,227,578 ▼ 41% vs 2022 (€ 5,428,983) Unfavourable step	€ 3,442,696 Cash 2024: € 3,442,696 ▲ 7% vs 2023 (€ 3,227,578) Favourable step	€ 1,825,334 Cash 2025: € 1,825,334 ▼ 47% vs 2024 (€ 3,442,696) Unfavourable step	▼ 47%
Retained profit	€ -3,597,933 Retained profit 2022: € -3,597,933 First fiscal year in the series	€ -6,222,497 Retained profit 2023: € -6,222,497 ▼ € 2.6 million vs 2022 (€ -3,597,933) Unfavourable step	€ -10,037,470 Retained profit 2024: € -10,037,470 ▼ € 3.8 million vs 2023 (€ -6,222,497) Unfavourable step	€ -15,340,124 Retained profit 2025: € -15,340,124 ▼ € 5.3 million vs 2024 (€ -10,037,470) Unfavourable step	▼ € 5.3 million
Balance sheet total	€ 6,670,178 Balance sheet total 2022: € 6,670,178 First fiscal year in the series	€ 4,121,517 Balance sheet total 2023: € 4,121,517 ▼ 38% vs 2022 (€ 6,670,178) Unchanged	€ 4,591,785 Balance sheet total 2024: € 4,591,785 ▲ 11% vs 2023 (€ 4,121,517) Unchanged	€ 3,468,754 Balance sheet total 2025: € 3,468,754 ▼ 24% vs 2024 (€ 4,591,785) Unchanged	▼ 24%
Employees (FTE)	-	4.6 Employees (FTE) 2023: 4.6 First fiscal year in the series	4.7 Employees (FTE) 2024: 4.7 ▲ 0.1 vs 2023 (4.6) Unchanged	5.6 Employees (FTE) 2025: 5.6 ▲ 0.9 vs 2024 (4.7) Unchanged	▲ 0.9

Key figures of AnimAb, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to AnimAb?

What happened at AnimAb in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2031 Virtus Bonarum Cellarum BV stepped down as director. NBB
2031 Participatiemaatschappij Vlaanderen NV stepped down as director. NBB
2031 ALBATROS BV stepped down as director. NBB
2031 SLL Consulting LLC stepped down as director. NBB
2031 Agri Investment Fund BV stepped down as director. NBB
2031 QBIC Venture Partners III stepped down as director. NBB
Jun 17, 2026 New annual accounts for financial year 2025: loss of € 5.3 million. Source: NBB ↗
2025 SLL Consulting LLC became a director. NBB

In short

From € 1.6 million loss in 2022 to € 5.3 million loss in 2025.

On average € 5,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Participatiemaatschappij Vlaanderen 20.9%

Agri Investment Fund 20.9%

QBIC III FUND 15.1%

VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY 14%

The stake of Participatiemaatschappij Vlaanderen, Agri Investment Fund, QBIC III FUND, VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY, V-Bio Fund 1 comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

AnimAb

The shares are held by Participatiemaatschappij Vlaanderen (20.9%), Agri Investment Fund (20.9%), QBIC III FUND (15.1%), VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY (14%) and V-Bio Fund 1 (10.3%).